Joe Rogan believes Robert F. Kennedy Jr’s appointment to lead the Department of Health and Human Services could prove beneficial for veterans seeking support.
Suicide is the number two cause of death among veterans under the age of 45, accounting for more than 6,000 deaths annually. Sadly, that number has been steadily increasing in recent years with the lack of proper healthcare and a reliance on prescription medications becoming more prevalent with each passing year. However, not all hope is lost for the brave men and women who served their country.
According to a report published by Stanford Medicine earlier this year, ibogaine — a plant-based psychoactive compound — safely led to improvements in depression, anxiety, and functioning among veterans with traumatic brain injuries. Unfortunately, ibogaine-assisted treatments are currently illegal in the United States and fall under the Schedule I category which includes drugs like heroin.
Rogan believes that with RFK Jr’s appointment, that could change leading to ibogaine therapies being made available to those in need stateside.
“Which, I think, is the best way to start it off because they’re the most deserving of it, they’re the people we ask of the most and there’s been a lot of people that have had some pretty profound changes take place because of psychedelic experiences,” Rogan said on his JRE podcast while discussing the possibility of treating military veterans with the psychoactive drug.
The FDA lists this powerful healing substance on Schedule 1, meaning “No therapeutic use and high potential for abuse.” Absurd. I will deschedule ibogaine and all psychedelic medicines. #Kennedy24https://t.co/H3S7gb8YPZ
— Robert F. Kennedy Jr (@RobertKennedyJr) January 9, 2024
Joe Rogan Guest Rick Strassman Offers His Take on Psychedelic-Assisted Therapy
Rick Strassman — Rogan’s guest on the show and a Professor of Psychiatry at the University of New Mexico — offered his thoughts on how ibogaine therapies could be implemented in the U.S.
“I think it’s going to need to be scaled up and what that scaling up looks like, still isn’t really worked out,” Strassman said. “I think they should develop special clinics where you wouldn’t actually be doing research and you wouldn’t need incredibly strong data to justify that kind of treatment. You would just need an indication that was helpful.
“You need to have a specialized therapist, pure drug… It wouldn’t be a Schedule 1 kind of restrictive research but it wouldn’t be just a wild-west ‘anybody and anything goes’… I think there needs to be some kind of middle institutional development where a lot of people can go who would benefit from psychedelic-assisted therapy.”